Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Caspase 3
/ metabolism
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cytochromes c
/ metabolism
DNA
/ metabolism
DNA Fragmentation
/ drug effects
Female
Metal Nanoparticles
/ chemistry
Mice
Oxidative Stress
/ drug effects
Sorafenib
/ pharmacology
Tumor Burden
/ drug effects
Zinc Oxide
/ pharmacology
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
02
2020
revised:
15
04
2020
accepted:
15
05
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
28
1
2021
Statut:
epublish
Résumé
Cancer, as a group, represents the most important cause of death worldwide. Unfortunately, the available therapeutic approaches of cancer including surgery, chemotherapy, radiotherapy, and immunotherapy are unsatisfactory and represent a great challenge as many patients have cancer recurrence and severe side effects. Methotrexate (MTX) is a well-established (antineoplastic or cytotoxic) chemotherapy and immunosuppressant drug used to treat different types of cancer, but its usage requires high doses causing severe side effects. Therefore, we need a novel drug with high antitumor efficacy in addition to safety. The aim of this study was the evaluation of the antitumor efficacy of zinc oxide nanoparticle (ZnO-NPs) and sorafenib alone or in combination on solid Ehrlich carcinoma (SEC) in mice. Sixty adult female Swiss-albino mice were divided equally into 6 groups as follows: control, SEC, MTX, ZnO-NPs, sorafenib, and ZnO-NPs+sorafenib; all treatments continued for 4 weeks. ZnO-NPs were characterized by TEM, zeta potential, and SEM mapping. Data showed that ZnO-NPs synergized with sorafenib as a combination therapy to execute more effective and safer anticancer activity compared to monotherapy as showed by a significant reduction (
Identifiants
pubmed: 32566073
doi: 10.1155/2020/1362104
pmc: PMC7275957
doi:
Substances chimiques
Antineoplastic Agents
0
Cytochromes c
9007-43-6
DNA
9007-49-2
Sorafenib
9ZOQ3TZI87
Caspase 3
EC 3.4.22.-
Zinc Oxide
SOI2LOH54Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1362104Informations de copyright
Copyright © 2020 Ahmed Nabil et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
pubmed: 17016424
Iran J Pharm Res. 2018 Fall;17(4):1328-1338
pubmed: 30568691
Anal Biochem. 1982 Oct;126(1):131-8
pubmed: 7181105
Anal Biochem. 1968 Oct 24;25(1):192-205
pubmed: 4973948
Mol Cancer Ther. 2009 Jan;8(1):152-9
pubmed: 19139124
Pure Appl Chem. 2009 Jan 1;81(6):1051-1063
pubmed: 20046887
Pharmaceutics. 2019 Nov 04;11(11):
pubmed: 31689932
Environ Toxicol. 2020 Apr;35(4):528-537
pubmed: 31821727
Cancer Res. 1990 Mar 1;50(5):1392-6
pubmed: 2302704
ScientificWorldJournal. 2012;2012:509838
pubmed: 23002387
Expert Opin Drug Deliv. 2010 Sep;7(9):1063-77
pubmed: 20716019
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Free Radic Biol Med. 2000 Dec;29(11):1106-14
pubmed: 11121717
Exp Ther Med. 2020 Jan;19(1):339-346
pubmed: 31853309
Cancer. 2008 Sep 1;113(5):1025-31
pubmed: 18618509
Nanoscale Res Lett. 2019 Dec 10;14(1):373
pubmed: 31823131
Food Chem Toxicol. 2015 Oct;84:154-60
pubmed: 26316185
Mol Biol Rep. 2019 Oct;46(5):4827-4841
pubmed: 31270760
ACS Nano. 2019 Nov 26;13(11):12912-12928
pubmed: 31651142
BMC Cancer. 2010 Oct 15;10:560
pubmed: 20950443
Cancer Res. 2008 Nov 1;68(21):8643-53
pubmed: 18974103
Arch Dermatol Res. 2013 Aug;305(6):495-500
pubmed: 23660995
Breast Cancer Res. 2013;15(4):R63
pubmed: 23938089
Chem Rev. 2018 Jul 25;118(14):6499-6515
pubmed: 29927236
Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59
pubmed: 15350294
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
PLoS One. 2014 Jan 22;9(1):e85891
pubmed: 24465768
J Drug Target. 2001;9(4):267-79
pubmed: 11697030
Int J Nanomedicine. 2017 Sep 05;12:6521-6535
pubmed: 28919752
Nano Lett. 2006 Aug;6(8):1794-807
pubmed: 16895376
Cell Death Differ. 2003 Jun;10(6):709-17
pubmed: 12761579
Arch Pharm Res. 2006 Oct;29(10):826-33
pubmed: 17121175
Clin Exp Pharmacol Physiol. 2017 Feb;44(2):235-243
pubmed: 27718258
Cancer Lett. 2020 Feb 1;470:134-140
pubmed: 31733288
J Control Release. 2020 May 10;321:222-235
pubmed: 32061620
J Adv Res. 2019 Mar 01;18:161-172
pubmed: 31032117
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1686-98
pubmed: 24055719
Microsc Res Tech. 2009 Mar;72(3):144-52
pubmed: 19130611
Redox Rep. 2001;6(2):77-90
pubmed: 11450987
Gastroenterol Clin Biol. 2006 Feb;30(2):304-6
pubmed: 16565667
Tumori. 1993 Aug 31;79(4):268-72
pubmed: 8249181
Yale J Biol Med. 2006 Dec;79(3-4):85-94
pubmed: 17940618
Int J Nanomedicine. 2019 May 27;14:3911-3928
pubmed: 31213808
J Ethnopharmacol. 2011 Apr 12;134(3):984-7
pubmed: 21251969
Anal Biochem. 1978 May;86(1):271-8
pubmed: 655387
Acta Pharmacol Sin. 2017 May;38(5):614-622
pubmed: 28344323
Oncol Rep. 2013 Apr;29(4):1285-92
pubmed: 23404427
Mol Cancer Ther. 2012 Oct;11(10):2284-93
pubmed: 22902857
Clin Transl Oncol. 2006 May;8(5):318-29
pubmed: 16760006
J Clin Pathol. 2001 May;54(5):356-61
pubmed: 11328833
Mater Sci Eng C Mater Biol Appl. 2017 Jan 1;70(Pt 1):889-896
pubmed: 27770966